Trial Profile
Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Nov 2023
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Chronic heart failure; Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms FAIR-HF2
- 02 Aug 2022 According to a CSL Vifor media release, Vifor Pharma has been acquired by CSL and renamed to CSL Vifor.
- 08 Dec 2016 New trial record